Key Points
- CEO Bobak Azamian sold 10,000 Tarsus Pharmaceuticals shares at an average price of $90.56, generating $905,600. The transaction was made under a pre-arranged Rule 10b5-1 plan and reduced his stake by 1.19%, leaving him with 827,991 shares.
- Tarsus reported quarterly revenue of $173.91 million, exceeding estimates, but its loss of $0.43 per share was wider than analysts expected. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $92.57.
- The stock opened at $82.77 and has a market capitalization of approximately $3.63 billion. Institutional investors own about 90.01% of the company, with major funds including BlackRock and Deep Track Capital increasing or initiating positions.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak Azamian sold 10,000 shares of the business's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $90.56, for a total value of $905,600.00. Following the sale, the chief executive officer directly owned 827,991 shares in the company, valued at approximately $74,982,864.96. The trade was a 1.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Tarsus Pharmaceuticals Stock Performance
Shares of NASDAQ TARS opened at $82.77 on Thursday. Tarsus Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $91.53. The firm has a market cap of $3.63 billion, a P/E ratio of -75.94 and a beta of 0.54. The stock has a fifty day moving average price of $67.53 and a two-hundred day moving average price of $66.45. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.17 and a current ratio of 3.20.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.24). The firm had revenue of $173.91 million during the quarter, compared to the consensus estimate of $169.65 million. Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%. Research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -2.4 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts have commented on TARS shares. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. Mizuho reduced their price objective on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an "outperform" rating for the company in a research report on Friday, July 31st. Oppenheimer lifted their price objective on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 12th. HC Wainwright reissued a "buy" rating and set a $88.00 target price on shares of Tarsus Pharmaceuticals in a research note on Thursday, July 9th. Finally, Jefferies Financial Group raised their target price on shares of Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the stock a "buy" rating in a report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $92.57.
View Our Latest Report on TARS
Institutional Investors Weigh In On Tarsus Pharmaceuticals
Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Tarsus Pharmaceuticals in the 2nd quarter worth about $242,705,000. Jupiter Topco LLC purchased a new stake in Tarsus Pharmaceuticals during the second quarter valued at about $176,834,000. California State Teachers Retirement System lifted its stake in Tarsus Pharmaceuticals by 5,971.9% during the second quarter. California State Teachers Retirement System now owns 2,288,813 shares of the company's stock valued at $144,058,000 after buying an additional 2,251,118 shares in the last quarter. Deep Track Capital LP boosted its holdings in shares of Tarsus Pharmaceuticals by 71.4% in the third quarter. Deep Track Capital LP now owns 3,000,000 shares of the company's stock worth $178,290,000 after buying an additional 1,250,000 shares during the period. Finally, Bank of America Corp DE acquired a new position in shares of Tarsus Pharmaceuticals in the second quarter worth about $75,099,000. 90.01% of the stock is owned by hedge funds and other institutional investors.
Tarsus Pharmaceuticals Company Profile
(
Get Free Report)
Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.
In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
